Digital X-ray Dementia Treatment Device Developer, "READYCURE Co.…
페이지 정보
본문
Digital X-ray Dementia Treatment Device Developer, "READYCURE Co., Ltd.,
" Selected for Ministry of SMEs and Startups’ Deep Tech TIPS
and Didimdol R&D Projects, Agreement Finalized
Recognized for its technological prowess with selection for the Ministry of SMEs
and Startups’ Deep Tech TIPS and Didimdol R&D projects, as well as successful investment attraction,
READYCURE aims to commercialize the digital X-ray-based dementia treatment device
"HeLaXON" both domestically and internationally.
ReadyCure Co., Ltd. (CEO Weon Kuu Chung), a developer of a dementia treatment system
utilizing digital X-rays to restore brain immune function through multiple mechanisms,
announced it finalized agreements on August 29 for the Ministry of SMEs and
Startups' Deep Tech TIPS and Startup Growth Technology Development Didimdol Project.
Deep Tech TIPS is a program supporting innovative, advanced technology-based startups.
When a private investor selects a promising startup and invests, government funds match the investment,
providing up to 1.7 billion KRW for R&D, commercialization, and overseas expansion.
Supported by the operator FuturePlay, ReadyCure has secured funding for talent acquisition
and technology advancement through this selection.
Additionally, the Didimdol Global R&D program, part of the Ministry's Startup Growth
Technology Development initiative, aims to foster small businesses' innovative technology development
and enhance their global market competitiveness, providing 120 million KRW over one year.
Through this project, ReadyCure plans to enhance its technology, strengthen patents,
and pursue market entry both domestically and internationally as scheduled.
Currently under development, ReadyCure’s dementia treatment system,
HeLaXON, is a digital X-ray-based medical device for dementia treatment,
gaining attention as an alternative to conventional therapies.
By focusing on restoring brain immune function to address dementia at its root
and improve or maintain cognitive abilities, CEO Weon Kuu Chung remarked,
“Unlike drugs that only aim to slow the disease, HeLaXON is free from drug-related side effects,
offering an innovative alternative to current treatments.”
The ReadyCure research team stated,
“We are continuously studying the positive effects of the multi-mechanisms
of digital X-rays on dementia treatment.
Based on the data gathered, we aim to secure the safety and efficacy of this new treatment approach,
paving the way for potential dementia treatments.”
CEO Weon Kuu Chung expressed his commitment, stating that with the foundation of
the Ministry’s Deep Tech TIPS and Didimdol Project support,
alongside proactive assistance from the program operators, he aims to secure Series A funding by the
first half of 2025 and focus on developing a dementia treatment device for full commercialization by 2026.
관련링크
- 이전글[Interview] Weon Kuu Chung, CEO of READYCURE: “Dementia Treatment is Possible with Low-Dose Radiation” 24.11.14
- 다음글ReadyCure, Developing a Digital Therapeutic for Dementia, Secures Investment from FuturePlay 24.11.14
댓글목록
등록된 댓글이 없습니다.
